For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Iclaprim | iclaprim 80 mg intravenous every 12 hours Iclaprim: Experimental treatment | 0 | None | 0 | 299 | 0 | 299 | View |
| Vancomycin | vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance Vancomycin: Active comparator | 1 | None | 1 | 302 | 1 | 302 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Renal and urinary disorders | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Product Issues | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |